Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 249270
Corporate User License Price USD 10500
Corporate User License Price INR 747810
Site License Price USD 7000
Site License Price INR 498540
Request a Quote

Report Title

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017



Executive Summary

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017

Summary

According to the recently published report Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017 Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report Muscarinic Acetylcholine Receptor M2 (CHRM2)-Pipeline Review, H1 2017 outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology and Genetic Disorders which include indications Alzheimer Disease, Overactive Bladder, Depression, Parkinson Disease, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Axillary Hyperhidrosis, Cognitive Disorders, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Rett Syndrome, Schizophrenia, Stroke and Urinary Incontinence.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)

The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Overview

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Companies Involved in Therapeutics Development

Allergan Plc

Anavex Life Sciences Corp

FemmePharma Global Healthcare Inc

Juniper Pharmaceuticals Inc

Karuna Pharmaceuticals Inc

TheraVida Inc

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Drug Profiles

(ANAVEX-273 + donepezil hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxybutynin chloride + pilocarpine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(oxybutynin chloride + rivastigmine)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(trospium chloride + xanomeline tartrate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-141-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANAVEX-273-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THVD-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Dormant Products

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Discontinued Products

Muscarinic Acetylcholine Receptor M2 (CHRM2)-Product Development Milestones

Featured News & Press Releases

May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference

May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings

Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017

Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers

Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer Disease Patients

Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer Disease

Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis

Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model

Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson Disease

Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate

Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer Patients Presented at AAIC 2016

Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer Patients at AAIC 2016

Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer Patients at AAIC 2016

Jul 12, 2016: Anavex to Present at the Alzheimer Association International Conference (AAIC) 2016

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Allergan Plc, H1 2017

Pipeline by Anavex Life Sciences Corp, H1 2017

Pipeline by FemmePharma Global Healthcare Inc, H1 2017

Pipeline by Juniper Pharmaceuticals Inc, H1 2017

Pipeline by Karuna Pharmaceuticals Inc, H1 2017

Pipeline by TheraVida Inc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Allergan Plc

Anavex Life Sciences Corp

FemmePharma Global Healthcare Inc

Juniper Pharmaceuticals Inc

Karuna Pharmaceuticals Inc

TheraVida Inc

Muscarinic Acetylcholine Receptor M2 (CHRM2) Therapeutic Products under Development, Key Players in Muscarinic Acetylcholine Receptor M2 (CHRM2) Therapeutics, Muscarinic Acetylcholine Receptor M2 (CHRM2) Pipeline Overview, Muscarinic Acetylcholine Receptor M2 (CHRM2) Pipeline, Muscarinic Acetylcholine Receptor M2 (CHRM2) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person